Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer.

Abraham M, Kordatou Z, Barriuso J, Lamarca A, Weaver JMJ, Cipriano C, Papaxoinis G, Backen A, Mansoor W.

PLoS One. 2019 Nov 27;14(11):e0224540. doi: 10.1371/journal.pone.0224540. eCollection 2019.

2.

Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas.

Capdevila J, Arqués O, Hernandez Mora JR, Matito J, Caratu G, Mancuso FM, Landolfi S, Barriuso J, Jimenez-Fonseca P, Lopez Lopez C, Garcia-Carbonero R, Hernando J, Matos I, Paolo N, Hernández-Losa J, Esteller M, Martínez-Cardús A, Tabernero J, Vivancos A, Palmer HG.

Clin Cancer Res. 2019 Oct 31. pii: clincanres.1266.2019. doi: 10.1158/1078-0432.CCR-19-1266. [Epub ahead of print]

PMID:
31672771
3.

Identification of areas for improvement in the management of bone metastases in patients with neuroendocrine neoplasms.

Lim KHJ, Raja H, D'Arienzo P, Barriuso J, McNamara MG, Hubner RA, Mansoor W, Valle JW, Lamarca A.

Neuroendocrinology. 2019 Oct 22. doi: 10.1159/000504256. [Epub ahead of print]

PMID:
31639796
4.

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice.

Lamarca A, Clouston H, Barriuso J, McNamara MG, Frizziero M, Mansoor W, Hubner RA, Manoharan P, O'Dwyer S, Valle JW.

J Clin Med. 2019 Oct 5;8(10). pii: E1630. doi: 10.3390/jcm8101630. Review.

5.

Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.

Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1365. doi: 10.1007/s00280-019-03964-6.

6.

Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration.

Lamarca A, Barriuso J, McNamara MG, Hubner RA, Manoharan P, Mansoor W, Valle JW.

Neuroendocrinology. 2019 Sep 17. doi: 10.1159/000503392. [Epub ahead of print]

PMID:
31527383
7.

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.

Saavedra C, Barriuso J, McNamara MG, Valle JW, Lamarca A.

Cancer Manag Res. 2019 Aug 8;11:7537-7556. doi: 10.2147/CMAR.S181439. eCollection 2019. Review.

8.

From presentation to paper: Gender disparities in oncological research.

Dijksterhuis WPM, Stroes CI, Tan WL, Ithimakin S, Calles A, van Oijen MGH, Verhoeven RHA, Barriuso J, Oosting SF, Ivankovic DK, Furness AJS, Bozovic-Spasojevic I, Gomez-Roca C, van Laarhoven HWM.

Int J Cancer. 2019 Aug 31. doi: 10.1002/ijc.32660. [Epub ahead of print]

PMID:
31472016
9.

Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.

Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, Barriuso J, Castaño Á, Benavent M, Alonso V, Riesco-Martínez MDC, Alonso-Gordoa T, Custodio A, Sánchez Cánovas M, Hernando Cubero J, López C, Lacasta A, Fernández Montes A, Marazuela M, Crespo G, Escudero P, Diaz JÁ, Feliciangeli E, Gallego J, Llanos M, Segura Á, Vilardell F, Percovich JC, Grande E, Capdevila J, Valle JW, García-Carbonero R.

J Clin Oncol. 2019 Oct 1;37(28):2571-2580. doi: 10.1200/JCO.19.00980. Epub 2019 Aug 7.

10.

Improvement of the Activity of a Fungal Versatile-Lipase Toward Triglycerides: An in silico Mechanistic Description.

Payá-Tormo L, Rodríguez-Salarichs J, Prieto A, Martínez MJ, Barriuso J.

Front Bioeng Biotechnol. 2019 Mar 29;7:71. doi: 10.3389/fbioe.2019.00071. eCollection 2019.

11.

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.

Rivera F, Romero C, Jimenez-Fonseca P, Izquierdo-Manuel M, Salud A, Martínez E, Jorge M, Arrazubi V, Méndez JC, García-Alfonso P, Reboredo M, Barriuso J, Muñoz-Unceta N, Jimeno R, López C.

Cancer Chemother Pharmacol. 2019 Jun;83(6):1175-1181. doi: 10.1007/s00280-019-03820-7. Epub 2019 Mar 29. Erratum in: Cancer Chemother Pharmacol. 2019 Dec;84(6):1365.

12.

18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis.

Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, ÓReilly D, Manoharan P, Valle JW.

J Hepatol. 2019 Jul;71(1):115-129. doi: 10.1016/j.jhep.2019.01.038. Epub 2019 Feb 21.

PMID:
30797051
13.

Biomarker concordance between primary colorectal cancer and its metastases.

Bhullar DS, Barriuso J, Mullamitha S, Saunders MP, O'Dwyer ST, Aziz O.

EBioMedicine. 2019 Feb;40:363-374. doi: 10.1016/j.ebiom.2019.01.050. Epub 2019 Feb 4.

14.

Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.

Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, McNamara MG, Hubner RA, Mansoor W, Manoharan P, Fazio N, Valle JW.

Neuroendocrinology. 2019;109(2):100-112. doi: 10.1159/000497336. Epub 2019 Jan 21.

PMID:
30703770
15.

Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, Zubairi I, Savulsky C, Reyderman L, Jia Y, Sweeting L, Greystoke A, Barriuso J, Kristeleit R.

Br J Cancer. 2019 Feb;120(4):379-386. doi: 10.1038/s41416-019-0377-x. Epub 2019 Jan 25.

16.

SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018).

González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R.

Clin Transl Oncol. 2019 Jan;21(1):55-63. doi: 10.1007/s12094-018-1980-7. Epub 2018 Dec 7.

17.

Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).

Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW.

Clin Transl Oncol. 2019 Jul;21(7):950-953. doi: 10.1007/s12094-018-1996-z. Epub 2018 Nov 30.

PMID:
30506132
18.

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.

Lamarca A, Galdy S, Barriuso J, Moghadam S, Beckett E, Rogan J, Backen A, Billington C, McNamara MG, Hubner RA, Cramer A, Valle JW.

PLoS One. 2018 Oct 18;13(10):e0206007. doi: 10.1371/journal.pone.0206007. eCollection 2018. Erratum in: PLoS One. 2019 Feb 15;14(2):e0212697.

19.

Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours.

Barriuso J, Custodio A, Afonso R, Alonso V, Astudillo A, Capdevila J, García-Carbonero R, Grande E, Jimenez-Fonseca P, Marazuela M, Rodríguez-Antona C, Aller J.

Cancer Treat Rev. 2018 Nov;70:209-222. doi: 10.1016/j.ctrv.2018.09.008. Epub 2018 Sep 26. Review.

PMID:
30292979
20.

Purification and characterization of a fungal laccase from the ascomycete Thielavia sp. and its role in the decolorization of a recalcitrant dye.

Mtibaà R, Barriuso J, de Eugenio L, Aranda E, Belbahri L, Nasri M, Martínez MJ, Mechichi T.

Int J Biol Macromol. 2018 Dec;120(Pt B):1744-1751. doi: 10.1016/j.ijbiomac.2018.09.175. Epub 2018 Sep 27.

PMID:
30268749
21.

Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair.

Lamarca A, Barriuso J, McNamara MG, Valle JW.

Cancer Treat Rev. 2018 Nov;70:168-177. doi: 10.1016/j.ctrv.2018.09.002. Epub 2018 Sep 8. Review.

PMID:
30218788
22.

Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.

Mendiola M, Redondo A, Heredia-Soto V, Herranz J, Berjón A, Hernández A, Miguel-Martín M, Crespo R, Barriuso J, Cruz P, Yébenes L, Peláez-García A, Castelo B, DE Molina AR, Feliu J, Hardisson D.

Anticancer Res. 2018 Sep;38(9):5393-5400. doi: 10.21873/anticanres.12869.

PMID:
30194194
23.

RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.

Casar B, Badrock AP, Jiménez I, Arozarena I, Colón-Bolea P, Lorenzo-Martín LF, Barinaga-Rementería I, Barriuso J, Cappitelli V, Donoghue DJ, Bustelo XR, Hurlstone A, Crespo P.

Nat Commun. 2018 Sep 5;9(1):3595. doi: 10.1038/s41467-018-05941-8.

24.

In Silico Analysis of the Quorum Sensing Metagenome in Environmental Biofilm Samples.

Barriuso J, Martínez MJ.

Front Microbiol. 2018 Jun 7;9:1243. doi: 10.3389/fmicb.2018.01243. eCollection 2018.

25.

Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.

Lamarca A, McCallum L, Nuttall C, Barriuso J, Backen A, Frizziero M, Leon R, Mansoor W, McNamara MG, Hubner RA, Valle JW.

Expert Rev Gastroenterol Hepatol. 2018 Jul;12(7):723-731. doi: 10.1080/17474124.2018.1489232. Epub 2018 Jun 28.

PMID:
29923433
26.

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Capdevila J, Teulé A, Barriuso J, Castellano D, Lopez C, Manzano JL, Alonso V, García-Carbonero R, Dotor E, Matos I, Custodio A, Casanovas O, Salazar R; EVERLAR study investigators.

Oncologist. 2019 Jan;24(1):38-46. doi: 10.1634/theoncologist.2017-0622. Epub 2018 May 23.

PMID:
29794066
27.

Role of quorum sensing and chemical communication in fungal biotechnology and pathogenesis.

Barriuso J, Hogan DA, Keshavarz T, Martínez MJ.

FEMS Microbiol Rev. 2018 Sep 1;42(5):627-638. doi: 10.1093/femsre/fuy022.

28.

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.

Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J, McNamara MG, Moghadam S, Rogan J, Mansoor W, Hubner RA, Clark C, Chakrabarty B, Valle JW.

Oncotarget. 2018 Feb 12;9(19):14922-14938. doi: 10.18632/oncotarget.24464. eCollection 2018 Mar 13.

29.

Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.

Miskolczi Z, Smith MP, Rowling EJ, Ferguson J, Barriuso J, Wellbrock C.

Oncogene. 2018 Jun;37(23):3166-3182. doi: 10.1038/s41388-018-0209-0. Epub 2018 Mar 16.

30.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Lamarca A, Barriuso J, Kulke M, Borbath I, Lenz HJ, Raoul JL, Meropol NJ, Lombard-Bohas C, Posey J, Faivre S, Raymond E, Valle JW.

Br J Cancer. 2018 Jan;118(2):181-188. doi: 10.1038/bjc.2017.402. Epub 2017 Nov 21.

31.

A novel, highly efficient β-glucosidase with a cellulose-binding domain: characterization and properties of native and recombinant proteins.

Méndez-Líter JA, Gil-Muñoz J, Nieto-Domínguez M, Barriuso J, de Eugenio LI, Martínez MJ.

Biotechnol Biofuels. 2017 Nov 6;10:256. doi: 10.1186/s13068-017-0946-2. eCollection 2017.

32.

New Horizons for Precision Medicine in Biliary Tract Cancers.

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX.

Cancer Discov. 2017 Sep;7(9):943-962. doi: 10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17. Review.

33.

Differential β-glucosidase expression as a function of carbon source availability in Talaromyces amestolkiae: a genomic and proteomic approach.

de Eugenio LI, Méndez-Líter JA, Nieto-Domínguez M, Alonso L, Gil-Muñoz J, Barriuso J, Prieto A, Martínez MJ.

Biotechnol Biofuels. 2017 Jun 23;10:161. doi: 10.1186/s13068-017-0844-7. eCollection 2017.

34.

Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, McNamara MG, Hubner RA, Garcia-Carbonero R, Meyer T, Valle JW, Barriuso J.

J Natl Cancer Inst. 2017 Jan 27;109(5). doi: 10.1093/jnci/djw277. Print 2017 Jan.

PMID:
28130474
35.

Evolutionary history of versatile-lipases from Agaricales through reconstruction of ancestral structures.

Barriuso J, Martínez MJ.

BMC Genomics. 2017 Jan 3;18(1):12. doi: 10.1186/s12864-016-3419-2.

36.

Telotristat ethyl: a new option for the management of carcinoid syndrome.

Lamarca A, Barriuso J, McNamara MG, Hubner RA, Valle JW.

Expert Opin Pharmacother. 2016 Dec;17(18):2487-2498. Epub 2016 Nov 16. Review.

PMID:
27817224
37.

Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.

Crespo G, Jiménez-Fonseca P, Custodio A, López C, Carmona-Bayonas A, Alonso V, Navarro M, Aller J, Sevilla I, Grande E, Gajate P, Alonso-Gordoa T, Matos I, Capdevila J, Nieto B, Barriuso J.

Future Oncol. 2017 Mar;13(7):615-624. doi: 10.2217/fon-2016-0434. Epub 2016 Nov 2.

PMID:
27802780
38.

Enzymatic fine-tuning for 2-(6-hydroxynaphthyl) β-D-xylopyranoside synthesis catalyzed by the recombinant β-xylosidase BxTW1 from Talaromyces amestolkiae.

Nieto-Domínguez M, Prieto A, Fernández de Toro B, Cañada FJ, Barriuso J, Armstrong Z, Withers SG, de Eugenio LI, Martínez MJ.

Microb Cell Fact. 2016 Oct 4;15(1):171.

39.

Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors.

Fotouhi O, Kjellin H, Larsson C, Hashemi J, Barriuso J, Juhlin CC, Lu M, Höög A, Pastrián LG, Lamarca A, Soto VH, Zedenius J, Mendiola M, Lehtiö J, Kjellman M.

J Clin Endocrinol Metab. 2016 Oct;101(10):3616-3627. Epub 2016 Jul 26.

40.

Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology.

Lamarca A, Mendiola M, Barriuso J.

Crit Rev Oncol Hematol. 2016 Sep;105:65-72. doi: 10.1016/j.critrevonc.2016.06.007. Epub 2016 Jun 16. Review.

PMID:
27372199
41.

Structural traits and catalytic versatility of the lipases from the Candida rugosa-like family: A review.

Barriuso J, Vaquero ME, Prieto A, Martínez MJ.

Biotechnol Adv. 2016 Sep-Oct;34(5):874-885. doi: 10.1016/j.biotechadv.2016.05.004. Epub 2016 May 14. Review.

PMID:
27188926
42.

Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?

Lamarca A, Elliott E, Barriuso J, Backen A, McNamara MG, Hubner R, Valle JW.

Cancer Treat Rev. 2016 Mar;44:26-41. doi: 10.1016/j.ctrv.2016.01.005. Epub 2016 Jan 25. Review.

PMID:
26855376
43.

Properties, structure, and applications of microbial sterol esterases.

Vaquero ME, Barriuso J, Martínez MJ, Prieto A.

Appl Microbiol Biotechnol. 2016 Mar;100(5):2047-61. doi: 10.1007/s00253-015-7258-x. Epub 2016 Jan 7. Review.

PMID:
26743653
44.

Phylogenetic and metabolic diversity of Tunisian forest wood-degrading fungi: a wealth of novelties and opportunities for biotechnology.

Daâssi D, Zouari-Mechichi H, Belbahri L, Barriuso J, Martínez MJ, Nasri M, Mechichi T.

3 Biotech. 2016 Jun;6(1):46. doi: 10.1007/s13205-015-0356-8. Epub 2016 Feb 4.

45.

Expression and properties of three novel fungal lipases/sterol esterases predicted in silico: comparison with other enzymes of the Candida rugosa-like family.

Vaquero ME, Prieto A, Barriuso J, Martínez MJ.

Appl Microbiol Biotechnol. 2015 Dec;99(23):10057-67. doi: 10.1007/s00253-015-6890-9. Epub 2015 Aug 14.

PMID:
26272094
46.

Identification and characterization of laccase-type multicopper oxidases involved in dye-decolorization by the fungus Leptosphaerulina sp.

Copete LS, Chanagá X, Barriuso J, López-Lucendo MF, Martínez MJ, Camarero S.

BMC Biotechnol. 2015 Aug 14;15:74. doi: 10.1186/s12896-015-0192-2.

47.

Novel pH-Stable Glycoside Hydrolase Family 3 β-Xylosidase from Talaromyces amestolkiae: an Enzyme Displaying Regioselective Transxylosylation.

Nieto-Domínguez M, de Eugenio LI, Barriuso J, Prieto A, Fernández de Toro B, Canales-Mayordomo Á, Martínez MJ.

Appl Environ Microbiol. 2015 Sep;81(18):6380-92. doi: 10.1128/AEM.01744-15. Epub 2015 Jul 6.

48.

Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.

Capdevila J, Sevilla I, Alonso V, Antón Aparicio L, Jiménez Fonseca P, Grande E, Reina JJ, Manzano JL, Alonso Lájara JD, Barriuso J, Castellano D, Medina J, López C, Segura Á, Carrera S, Crespo G, Fuster J, Munarriz J, García Alfonso P.

BMC Cancer. 2015 Jul 4;15:495. doi: 10.1186/s12885-015-1512-6.

49.

Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms.

Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members.

Endocr Relat Cancer. 2015 Aug;22(4):657-64. doi: 10.1530/ERC-15-0119. Epub 2015 Jun 25.

PMID:
26113608
50.

Zebrafish in oncology.

Barriuso J, Nagaraju R, Hurlstone A.

Aging (Albany NY). 2015 May;7(5):286-7. No abstract available.

Supplemental Content

Loading ...
Support Center